MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31

MACROGENICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$3.33+0.08 (+2.46%)

Close on Oct 19, 2026

Market cap: $211.77M
P/E (TTM): –
Dividend yield: –

MACROGENICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	150	150	59	152	77	105	64	60	158	92	101	48	58	64	57
Cost of Revenue	0	0.85	0.62	3.35	2.65	0	0	–	–	–	–	–	–	–	–
Gross Profit	150	149	58	149	75	105	64	–	–	–	–	–	–	–	–
Research & Development	147	177	167	207	215	193	195	191	147	122	98	70	47	45	41
General & Administrative	39	71	52	59	63	43	46	41	33	30	23	16	11	10	11
Total Costs & Expenses	222	261	227	273	280	236	241	231	180	152	121	86	58	56	52
Operating Income	-73	-111	-168	-121	-203	-131	-177	-171	-22	-60	-20	-38	0.37	8.21	5.25
Interest Expense	8.51	1.12	1.43	0	0	–	–	–	–	–	–	–	–	–	–
Interest & Investment Income	3.40	5.60	4.00	1.70	2.00	0.80	3.40	2.30	2.40	2.30	0.20	–	–	–	–
Other Non-Operating Income	6.06	9.42	9.69	1.66	0.68	1.32	25	-0.25	2.52	1.51	0.04	0.00	-0.63	0.16	1.47
Asset Impairment Charges	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0.01	0.06	-0.11	0	0	–	–	–	–	–	–	–	–	–	–
Pretax Income	-75	-66	-9.06	-120	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	-0.67	0.94	0	0	0	0	0	0	0	0	0	0	0	0	–
Net Income	-75	-67	-9.06	-120	-202	-130	-152	-171	-20	-59	-20	-38	-0.26	8.36	6.72
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	-38	-0.26	–	–
EPS (Basic)(per share)	-1.18	-1.07	-0.15	-1.95	-3.37	-2.47	–	–	-0.54	-1.69	-0.63	-1.40	-0.04	0.00	0.00
EPS (Diluted)(per share)	-1.18	-1.07	-0.15	-1.95	-3.37	-2.47	–	–	-0.54	-1.69	-0.63	-1.40	-0.04	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	63	63	62	61	60	52	48	41	36	35	32	27	6.85	1.08	1.03
Shares Outstanding (Diluted, Weighted)(shares)	63	63	62	61	60	52	48	41	36	35	32	27	6.85	1.08	1.03
EBITDA	-66	-103	-159	-110	-192	-119	-165	-162	-15	-52	-17	-36	1.57	9.21	6.35

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 89.2%
Operating margin: -24.3%
Net margin: -8.7%
Return on equity, FY2025: -86.9%

Financial strength

Current ratio: 2.96
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 104.7%

Valuation

P/E ratio: –
Price to sales: 1.26
Price to book: 4.94
Dividend yield: –